KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Emergent BioSolutions (EBS) over the last 14 years, with Dec 2024 value amounting to $24.3 million.

  • Emergent BioSolutions' Other Operating Expenses rose 58.94% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.4 million, marking a year-over-year decrease of 20.45%. This contributed to the annual value of $24.3 million for FY2024, which is 67.25% down from last year.
  • As of FY2024, Emergent BioSolutions' Other Operating Expenses stood at $24.3 million, which was down 67.25% from $74.2 million recorded in FY2023.
  • Emergent BioSolutions' Other Operating Expenses' 5-year high stood at $848.3 million during FY2021, with a 5-year trough of $24.3 million in FY2024.
  • Its 3-year average for Other Operating Expenses is $286.1 million, with a median of $74.2 million in 2023.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 42.14% in 2021, then tumbled by 90.23% in 2023.
  • Emergent BioSolutions' Other Operating Expenses (Yearly) stood at $596.8 million in 2020, then spiked by 42.14% to $848.3 million in 2021, then decreased by 10.44% to $759.7 million in 2022, then crashed by 90.23% to $74.2 million in 2023, then crashed by 67.25% to $24.3 million in 2024.